Cardiovascular disease is a leading cause of morbidity and mortality in patients who have undergone solid organ transplantation. Despite this, limited evidence exists for how to appropriately identify and mitigate cardiovascular risk in this population. In this blog, we discuss the management of dyslipidemia in transplant recipients.
Icosapent Ethyl for Prevention of Cardiovascular Disease: Worth the Hype or Fishing for a Place in Therapy?
Omega-3 fatty acids have been associated with lowering TG; however, robust data for clinical outcomes have been lacking until the recent publication of the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT).2,3 This blog will give a brief review of historical evidence, detail differences in fish oil supplements, and provide considerations for the role of Vascepa (icosapent ethyl) in high-risk patients with dyslipidemia.